Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).

ABSTRACT:

Purpose

Ki67 assessed at diagnosis (Ki67_baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki67_2week) is associated with clinical benefit from endocrine therapies and residual Ki67 (Ki67_2week) with recurrence-free survival. The aim was to define the association between Ki67_baseline and after aromatase inhibitor (AI) exposure ∆Ki67_2week and Ki67_2week with key prognostic and biologic factors utilising data from the POETIC study.

Patients and methods

In POETIC 4480 postmenopausal patients with primary ER and/or PgR + breast cancer were randomised 2:1 to 2 weeks' presurgical AI (anastrozole or letrozole) or no presurg

SUBMITTER: Bliss JM 

PROVIDER: S-EPMC10099675 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature